CYBN cybin.com: מקדם חוב לטווח ארוך להון

Cybin Inc. relies on patent protection for its exclusive anti-depressant formulas, which will enable the company to exercise pricing power over its drugs following certification. The business is investing in neurobiology and the development of smart delivery methods for modified molecules. This chart reflects the current share price of 0.20, underscoring the status of a recognized visionary that has received FDA confirmation of the breakthrough nature of its developments.

Cybin Inc. is investing in bioscreening automation and IT molecular modeling, which requires significant capital expenditures for the technology stack. When analyzing financial leverage via long-term debt, an investor assesses the ratio of liabilities with a maturity of over one year to equity to determine the extent of the company's reliance on borrowed funds and its overall solvency.